Innate Pharma Stock Target Price and Analyst Consensus
| IPHA Stock | USD 1.54 0.04 2.67% |
The current analyst and expert consensus on Innate Pharma is Strong Buy, with 3 strong buy opinions. The current projected Innate Pharma target price consensus is 7.55 with 5 analyst opinions. Check out Macroaxis Advice on Innate Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.The most common way Innate Pharma analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Innate Pharma executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Innate Pharma. We strongly encourage you to use your own analysis of Innate Pharma to validate this buy or sell advice. Innate Pharma buy-or-sell recommendation module provides average expert sentiment on the projected Innate Pharma target price to derive its highest and lowest estimates based on projected price volatility of 5.0595.
Lowest Forecast 6.87 | Highest Forecast 8.38 | Target Price 7.55 |
Innate |
It's important to approach Innate Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Innate Pharma price targets
Innate Pharma's stock target price is an estimate of its future price, usually made by analysts. Using Innate Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at Innate Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Innate Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Innate Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Innate Pharma is a key component of Innate Pharma valuation and have some predictive power on the future returns of a Innate Pharma.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | Momentum Invested few shares | |
 | Disruptive Technologies Invested few shares | |
 | Dividend Beast Invested over 50 shares | |
 | Macroaxis Picks Invested over 60 shares | |
 | Macroaxis Index Invested few shares | |
 | Business Services Invested few shares | |
 | Investor Favorites Invested over 200 shares | |
 | Driverless Cars Invested over 200 shares | |
 | Banking Invested over 40 shares | |
Check out Macroaxis Advice on Innate Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Please note, the presentation of Innate Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innate Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innate Pharma's management manipulating its earnings.